May 23, 2016
Via EDGAR
Suzanne Hayes
Assistant Director
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3561
Re: | Reata Pharmaceuticals, Inc. |
Registration Statement on Form S-1 (as amended)
File No. 333-208843
Ladies and Gentlemen:
On behalf of Reata Pharmaceuticals, Inc. (the “Company”), and pursuant to with Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned hereby requests that the effective date of the above referenced Registration Statement on Form S-1 be accelerated to 4:00 p.m., Washington, D.C. time, on May 25, 2016, or as soon as practicable thereafter.
The Company hereby acknowledges that:
• | should the Securities and Exchange Commission (the “Commission”) or the staff of the Division of Corporation Finance (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; |
• | the action of the Commission or the Staff, acting pursuant to delegated authority in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
• | the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
Thank you for your assistance in this matter.
Reata Pharmaceuticals, Inc.
2801 Gateway Drive, Suite 150
Irving, Texas 75063
www.reatapharma.com
Very truly yours, | ||
Reata Pharmaceuticals, Inc. | ||
By: | /s/ J. Warren Huff | |
Name: | J. Warren Huff | |
Title: | Chief Executive Officer |